Enimmune Balance Sheet Health
Financial Health criteria checks 5/6
Enimmune has a total shareholder equity of NT$431.4M and total debt of NT$43.1M, which brings its debt-to-equity ratio to 10%. Its total assets and total liabilities are NT$604.8M and NT$173.5M respectively.
Key information
10.0%
Debt to equity ratio
NT$43.12m
Debt
Interest coverage ratio | n/a |
Cash | NT$379.80m |
Equity | NT$431.36m |
Total liabilities | NT$173.46m |
Total assets | NT$604.83m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6564's short term assets (NT$465.2M) exceed its short term liabilities (NT$171.7M).
Long Term Liabilities: 6564's short term assets (NT$465.2M) exceed its long term liabilities (NT$1.8M).
Debt to Equity History and Analysis
Debt Level: 6564 has more cash than its total debt.
Reducing Debt: 6564's debt to equity ratio has increased from 0% to 10% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6564 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6564 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 12.6% each year.